Fatty acids are essential for survival, acting as bioenergetic substrates, structural
components and signalling molecules. Given their vital role, cells have evolved mechanisms …

Background Non-alcoholic fatty liver disease, or as recently proposed 'metabolic-associated
fatty liver disease'(MAFLD), is characterized by pathological accumulation of triglycerides …

Metformin is a first-line therapy for the treatment of type 2 diabetes, due to its robust glucose-
lowering effects, well-established safety profile, and relatively low cost. While metformin has …

Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty
liver disease (NAFLD). However, no pharmacological agents are currently approved in the …

Elevated liver de novo lipogenesis contributes to non-alcoholic steatohepatitis (NASH) and
can be inhibited by targeting acetyl-CoA carboxylase (ACC). However, hypertriglyceridemia …

Autophagic pathways cross with lipid homeostasis and thus provide energy and essential
building blocks that are indispensable for liver functions. Energy deficiencies are …

Background and Aims Advanced fibrosis attributable to NASH is a leading cause of end‐
stage liver disease. Approach and Results In this phase 2b trial, 392 patients with bridging …

Glucose and fructose are closely related simple sugars, but fructose has been associated
more closely with metabolic disease. Until the 1960s, the major dietary source of fructose …

Background & Aims De novo lipogenesis is increased in livers of patients with nonalcoholic
steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step in this …

Background The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing
worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver …